Ó²Ö¬õ£¸¨Ã¸AÈ¥±¥ºÍø1ÔÚÒȵº¦Âϸ°ûÖеÄ×÷Óü°»úÖÆÑо¿

·¢²¼Ê±¼ä£º2018-11-27 18:58
¡¾ÕªÒª¡¿£ºÓ²õ¥õ£¸¨Ã¸AÈ¥±¥ºÍø1(SCD1)Ö÷Òª¶¨Î»ÓÚÄÚÖÊÍøĤÉÏ,ÔÚµ÷½ÚÖ¬´úлÒÔ¼°ÒȵºËØÃô¸ÐÐÔ·½ÃæÆðµ½ÖØÒª×÷Óá£Ïà¹ØÎÄÏ×±¨µÀ,È«ÉíÐÔSCD1(-/-)ÇóýµÄob/obСÊó,ËäÈ»ÒȵºËØÃô¸ÐÐÔÏÔÖø¸ÄÉÆ,µ«Òȵº¹¦ÄܳöÏÖÑÏÖØËðÉË,¼´ÒȵºËغϳɼ°·ÖÃÚÑÏÖز»×ã,¾ßÌå·Ö×Ó»úÖƲ»Çå[1]¡£Òò´Ë,±¾ÎÄÖ¼ÔÚ̽¾¿SCD1ÔÚÒȵº¦Âϸ°û¹¦Äܺʹæ»î·½ÃæµÄ×÷ÓÃ,²¢Ì½Ë÷Ïà¹ØµÄµ÷½Ú»úÖÆ¡£Ê×ÏÈ,ÔÚ´óÊóÒȵº¦Âϸ°ûϵINS-1ÖÐÔËÓÃRNA¸ÉÈż¼Êõ,½µµÍϸ°ûÄÚSCD1µÄ±í´ï,½ø¶ø½øÐи߼ش̼¤µÄÒȵºËØ·ÖÃÚʵÑé(KSIS)²¢¼ì²âÒȵºËغ¬Á¿¡£½á¹û±íÃ÷,¸ÉÈÅSCD1µÄ±í´ï,ÆäKSIS¹¦ÄܺÍÒȵºËغ¬Á¿¾ùÏÔÖøϽµ¡£½Ó×Å,ÔÚINS-1ϸ°ûÖйý±í´ï»ò¸ÉÈÅSCD1,¼ì²âÒȵº¦Âϸ°ûÌØÒìÐÔת¼Òò×ӵıí´ïˮƽ¡£½á¹û·¢ÏÖ,¹ý±í´ïSCD1ÏÔÖøÔö¼Ó¼¡ëìĤÏËάÈâÁö°©»ùÒòͬԴÎïA»ùÒò(MafA)µÄµ°°×±í´ïˮƽ;¸ÉÈÅSCD1ÏÔÖøÒÖÖÆMafAµÄµ°°×±í´ïˮƽ,µ«SCD1¶ÔMafAµÄmRNAˮƽ²¢ÎÞÃ÷ÏÔÓ°Ïì¡£½øÒ»²½Ñо¿±íÃ÷,SCD1ͨ¹ýÆä×é°±ËáºÐÓëMafAÏ໥×÷ÓÃ,±ÜÃâMafAµ°°×½µ½â,´Ó¶øÔö¼ÓMafAµÄµ°°×Îȶ¨ÐÔ¡£²¡Àíѧ´Ì¼¤ÎïÈçÒÂùËØ»òÑ×Ö¢Òò×ÓIL-1¦Â×÷ÓÃÒȵº¦Âϸ°û,Ũ¶ÈÒÀÀµÐÔ½µµÍSCD1ÒÔ¼°MafAµÄµ°°×±í´ïˮƽ¡£¸üΪÖØÒªµÄÊÇ,¹ý±í´ïSCD1Äܹ»ÄæתÒÂùËØ»òIL-1¦ÂÒýÆðµÄMafAµ°°×ˮƽ½µµÍ¡£IL-1¦Â²»½öÃ÷ÏÔ½µµÍSCD1ÓëMafAÖ®¼äµÄÏ໥×÷ÓÃ,ÇÒÔö¼ÓMafAµÄ·ºËØ»¯Ë®Æ½¡£¹ý±í´ïSCD1²»½öÄܹ»²¿·ÖÈ¡ÏûIL-1¦ÂËùÒýÆðµÄMafA·ºËØ»¯ÐÞÊÎˮƽµÄÔö¼Ó,ÇÒÄܹ»ÄæתIL-1¦ÂËùÔì³ÉµÄINS-1ϸ°ûKSIS¹¦ÄÜÒÔ¼°ÒȵºËغ¬Á¿µÄ½µµÍ¡£×ÛÉÏËùÊö,±¾Ñо¿½ÒʾÁË,»ù´¡×´Ì¬ÏÂSCD1ͨ¹ýÓëת¼Òò×ÓMafAÏ໥×÷ÓÃÔö¼ÓMafAµÄµ°°×Îȶ¨ÐÔ¡£ËðÉËÒòËش̼¤ÏÂ,ÓÉÓÚSCD1ÓëMafAµÄÏ໥×÷ÓüõÈõ,MafA·ºËØ»¯ÐÞÊÎÔö¼Óµ¼Öµ°°×Îȶ¨ÐÔ½µµÍ,½ø¶øÔì³ÉÒȵº¦Âϸ°û¹¦ÄÜÕÏ°­¡£±¾Ñо¿·á¸»ÁËÈËÃǶÔSCD1ÔÚÒȵº¦Âϸ°ûÖеÄÉúÎïѧ¹¦ÄܵÄÈÏʶ,ΪÌÇÄò²¡µÄÖÎÁÆÌṩÁËеÄÖÎÁưеãÓëÀíÂÛÒÀ¾Ý¡£
[Abstract]:Desaturase 1 (SCD1) is mainly located on the endoplasmic omentum and plays an important role in regulating lipid metabolism and insulin sensitivity. It has been reported that the insulin sensitivity of ob/ob mice knockout with systemic SCD1 (- / -) is significantly improved, but the islet function is seriously damaged, that is, the synthesis and secretion of insulin is seriously inadequate, and the specific molecular mechanism is unclear [1]. Therefore, the purpose of this study is to explore the role of SCD1 in the function and survival of islet β cells and to explore the related regulatory mechanisms. Firstly, RNA interference technique was used to reduce the expression of SCD1 in rat islet β cell line INS-1, and then the hyperkalemic insulin secretion experiment (KSIS) was carried out and the insulin content was measured. The results showed that the KSIS function and insulin content decreased significantly after interfering with the expression of SCD1. Then, overexpression or interference of SCD1, in INS-1 cells was used to detect the expression of specific transcription factors in islet β cells. The results showed that overexpression of SCD1 significantly increased the expression of (MafA) of oncogene homologue A in fibrosarcoma of tendon, interfered with SCD1 significantly inhibited the expression of MafA, but SCD1 had no significant effect on the mRNA level of MafA. Further studies showed that SCD1 could avoid the degradation of MafA protein and increase the protein stability of MafA by interacting with MafA by its histidine box. The expression of SCD1 and MafA protein was decreased in a dose-dependent manner by pathological stimulators such as chlortetracycline or inflammatory factor IL-1 β. More importantly, overexpression of SCD1 could reverse the decrease of MafA protein level induced by SCD1 or IL-1 β. IL-1 β not only decreased the interaction between SCD1 and MafA, but also increased the level of MafA ubiquification. Overexpression of SCD1 could not only partially cancel the increase of MafA ubiquitin modification induced by IL-1 β, but also reverse the decrease of KSIS function and insulin content of INS-1 cells induced by IL-1 β. In conclusion, this study revealed that SCD1 enhances the protein stability of MafA by interacting with transcription factor MafA. Under the stimulation of injury factors, the interaction between SCD1 and MafA was weakened, and the increase of MafA ubiquitin modification led to the decrease of protein stability, which resulted in the dysfunction of islet β cells. This study enriches the understanding of the biological function of SCD1 in islet β cells and provides a new therapeutic target and theoretical basis for the treatment of diabetes mellitus.
¡¾Ñ§Î»ÊÚÓ赥λ¡¿£ºÄϾ©Ò½¿Æ´óѧ
¡¾Ñ§Î»¼¶±ð¡¿£ºË¶Ê¿
¡¾Ñ§Î»ÊÚÓèÄê·Ý¡¿£º2015
¡¾·ÖÀàºÅ¡¿£ºR587.1

¡¾ÏàËÆÎÄÏס¿

Ïà¹ØÆÚ¿¯ÂÛÎÄ Ç°10Ìõ

1 ;¡°Èð½ð¹ú¼ÊÄÚ·ÖÃÚÂÛ̳-Òȵº¦Âϸ°ûÑо¿¡±»áѶ¼°Õ÷ÎÄ֪ͨ(µÚ¶þÂÖ)[J];ÖлªÄÚ·ÖÃÚ´úлÔÓÖ¾;2006Äê04ÆÚ

2 ºÏäÐ;ËÕºã;;Òȵº¦Âϸ°ûËðÉ˵ķÖ×Ó»úÖÆ̽ÌÖ[J];ʵÓÃÌÇÄò²¡ÔÓÖ¾;2011Äê06ÆÚ

3 ÑîÊçÇï;;Òȵº¦Âϸ°ûÁö[J];¹ãÎ÷ҽѧ;1987Äê01ÆÚ

4 º«·ïÀ¼;Òȵº¦Âϸ°ûÁö(¸½13ÀýÁÙ´²·ÖÎö)[J];¹ã¶«Ò½Ñ§;1988Äê04ÆÚ

5 ͯÃûÈð,ÌïÐÂÁ¼;ÕöÑÛ»èÃÔ1ÔµÄÒȵº¦Âϸ°û°©1Àý±¨¸æ[J];ÐÂҽѧ;1988Äê09ÆÚ

6 Çñ×ÓÇ«;Ñî´«Ö®;Áõ¹ãºÍ;;ÎóÕïΪñ¯²¡µÄÒȵº¦Âϸ°ûÁö2Àý[J];ÁÙ´²ÎóÕïÎóÖÎ;1988Äê03ÆÚ

7 ÕÅÈð¾ü;Òȵº¦Âϸ°ûÁö1Àý[J];ɽ¶«Ò½Ò©;1997Äê08ÆÚ

8 ½¯Ðñ³¬;л־·¼;ÕÂÎÀƽ;;Òȵº¦Âϸ°û·¢ÓýÓëÔÙÉúµÄÑо¿½øÕ¹[J];Öйú²¡ÀíÉúÀíÔÓÖ¾;2013Äê10ÆÚ

9 åÌÊï¹â,Ëï½ð·ï;Òȵº¦Âϸ°ûÁö5ÀýÎóÕïÔ­Òò·ÖÎö[J];ɽ¶«Ò½Ò©;2000Äê11ÆÚ

10 ºÂÊç÷,½¯µ¤·å;³¤ÆÚÎóÕïµÄÒȵº¦Âϸ°ûÁö1Àý±¨¸æ[J];Öйú×ÛºÏÁÙ´²;2000Äê04ÆÚ

Ïà¹Ø»áÒéÂÛÎÄ Ç°10Ìõ

1 ·ÑÓñ¶ð;½ðÑ©¹â;;ÂÅ´ÎÎóÕïΪ½ßÖ¢µÄÒȵº¦Âϸ°ûÁöÒ»Àý[A];2006ÄêÕã½­Ê¡¾«Éñ²¡Ñ§Ñ§Êõ»áÒéÂÛÎÄ»ã±à[C];2006Äê

2 Áõ¾²;ÌïÀûÃñ;¹ùÜç;ÍõÈñ;·®å­ÕÜ;ÓàìÇ;;´óÊóÄÚÂð·ÈëĶÔÒȵº¦Âϸ°ûËðÉ˵ı£»¤×÷ÓÃ[A];2006ÄêÖлªÒ½Ñ§»áÌÇÄò²¡·Ö»áµÚÊ®´ÎÈ«¹úÌÇÄò²¡Ñ§Êõ»áÒéÂÛÎļ¯[C];2006Äê

3 ÁÖ½¨Á¢;ºî½¨Ã÷;¸ßÕþÄÏ;³Â¸Õ;»Æ»Û±ò;ο¡Æ½;Áº¼ÌÐË;;Ó¦ÓÃϸ°ûƬ²ã¼¼ÊõÑо¿Òȵº¦Âϸ°ûµÄϸ°û±£»¤[A];ÖлªÒ½Ñ§»áµÚʮһ´ÎÈ«¹úÄÚ·ÖÃÚѧѧÊõ»áÒéÂÛÎÄ»ã±à[C];2012Äê

4 Áú½¡;ËÕÑÞÐÂ;µË»ª´Ï;;Ö¬ÁªËØ¿¹Òȵº¦Âϸ°ûÖ¬ÐÔµòÍö¼°Æä»úÖÆ[A];ÖлªÒ½Ñ§»áµÚʮһ´ÎÈ«¹úÄÚ·ÖÃÚѧѧÊõ»áÒéÂÛÎÄ»ã±à[C];2012Äê

5 Àîɺɺ;¿×µÂÃ÷;Àîѩ÷;;ʹÓÃÒÅ´«Ñ§¿Éʾ×Ùת»ùÒò°ßÂíÓã¼¼Êõ½øÐм×ÏõßòÓÕµ¼Òȵº¦Âϸ°ûÆÆ»µºÍÔÙÉúµÄ³õ²½Ñо¿[A];2010Äê¹óÖÝÊ¡ÖÐÎ÷Ò½½áºÏѧ»áÄÚ·ÖÃÚѧÊõ»áÒéÂÛÎļ¯[C];2010Äê

6 ¹¹úêÍ;Ôø·²ÐÇ;·½×ÓÁú;;×¢ÉäÖØ×éÈËÉú³¤¼¤ËضÔÔ˶¯´óÊóÒȵº¦Âϸ°ûÐÎ̬ºÍ¹¦ÄܵÄÓ°Ïì[A];2002ÄêµÚ9½ìÈ«¹úÔ˶¯Ò½Ñ§Ñ§Êõ»áÒéÂÛÎÄÕªÒª»ã±à[C];2002Äê

7 ÕźêÀû;ÂæÌìºì;·ëÁä;ÕÔô§;ÀîÎÄÒã;Ðì¼Ñ;Àîê½;ÂÞÃô;;¶à·¢ÐÔÄÚ·ÖÃÚÖ×Áö1ÐÍ»ùÒò¶ÔÒȵº¦Âϸ°û·¢ÓýºÍ·Ö»¯×÷ÓõÄÑо¿[A];2006ÄêÖлªÒ½Ñ§»áÌÇÄò²¡·Ö»áµÚÊ®´ÎÈ«¹úÌÇÄò²¡Ñ§Êõ»áÒéÂÛÎļ¯[C];2006Äê

8 ÖÜÁÕ;ѦҫÃ÷;Éò½à;¸ß·½;;ÒȵíËضÔÌåÍâÅàÑøÒȵº¦Âϸ°ûÒȵºËØ·ÖÃÚÓ°ÏìµÄ·Ö×Ó»úÖÆ[A];ÖлªÒ½Ñ§»áµÚÁù´ÎÈ«¹úÄÚ·ÖÃÚѧÊõ»áÒéÂÛÎÄ»ã±à[C];2001Äê

9 Àîíµ;ºÎÇ廪;¹úºº°î;»ÆÐãÇå;ÂúÓÀ;·ÓÀ¸Õ;ÖÜÓ­Éú;ÍõÊã;À轡;;µÍÃܶÈÖ¬µ°°×Ó뼫µÍÃܶÈÖ¬µ°°×ÒýÆðÒȵº¦Âϸ°ûÑõ»¯ËðÉË×÷ÓõĻúÖÆ̽ÌÖ[A];µÚËĽìÈ«¹úѪ֬·ÖÎöÓëÁÙ´²Ñ§ÊõÑÐÌÖ»áôߵھŽìÈ«¹úÖ¬µ°°×ѧÊõ»áÒéÂÛÎÄ»ã±à[C];2008Äê

10 ÕÔÓñ·å;ÅὨÃ÷;ÖìÔËÁú;³Â³¿;;ÑÇÓÍËáͨ¹ýË«ÐźÅ;¾¶¼¤»î´óÊóÒȵº¦Âϸ°ûÉÏATPÃô¸ÐÐÔ¼ØͨµÀ[A];2008ÄêÉñ¾­ÄÚ·ÖÃÚôßÉñ¾­ÃâÒßÄÚ·ÖÃÚѧÊõÑÐÌÖ»áÂÛÎÄÕªÒª»ã±à[C];2008Äê

Ïà¹ØÖØÒª±¨Ö½ÎÄÕ ǰ10Ìõ

1 ¼ÇÕß °×Òã;µ÷¿ØÒȵº¦Âϸ°û´ú³¥ÐÔÔöֳлúÖƱ»·¢ÏÖ[N];ÖйúÒ½Ò©±¨;2014Äê

2 ÎâÒ»¸£;½©ÖªÒû¶ÔÒȵº¦Âϸ°ûËðÉËÓÐÐÞ¸´×÷ÓÃ[N];ÖйúÒ½Ò©±¨;2005Äê

3 ·ëÎÀ¶«;Íâ·ÖÃÚϸ°ûÖ±½Óת»¯Òȵº¦Âϸ°û»ñµÃ³É¹¦[N];¿Æ¼¼ÈÕ±¨;2008Äê

4 ½â·Å¾ü×ÜÒ½ÔºÄÚ·ÖÃÚ¿ÆÖ÷ÈÎҽʦ Å˳¤Óñ;½µÌÇͬʱÎðºöÂÔÒȵº¦Âϸ°û[N];½¡¿µ±¨;2010Äê

5 ÖÐɽ´óѧ¸½ÊôµÚ¶þÒ½ÔºÄÚ·ÖÃÚ¿ÆÖ÷ÈÎҽʦ ³Ìèë ½ÌÊÚ;¶ùͯÌÇÄò²¡»¼²¡ÂÊÃ÷ÏÔÔö¼Ó[N];½¡¿µÊ±±¨;2008Äê

6 ;Ò»Ïß½µÌÇÒ©Îï´æÔÚÑÏÖØÏÈÌì²»×ã[N];ÎÀÉúÓëÉú»î±¨;2007Äê

7 ±¾±¨¼ÇÕß¡¡ÕÔÉÜ»ª;¹ØÓÚ¡°¸Éϸ°ûÒÆÖ²ÖÎÓúÌÇÄò²¡¡±[N];½¡¿µÊ±±¨;2003Äê

8 Ö£Ù»âù;³¦´ÙÒÈËØÑо¿´øÀ´½µÌÇÐÂÀíÄî[N];ÖйúÒ½Ò©±¨;2010Äê

9 ³Â½ðΰ;Ò©Ãû²îÒÔºÁÀå ҩЧʧ֮ǧÀï[N];±£½¡Ê±±¨;2007Äê

10 Îâ¼Í;ÓªÔìÉúÃüµÄ´ºÌì[N];´óÖڿƼ¼±¨;2000Äê

Ïà¹Ø²©Ê¿Ñ§Î»ÂÛÎÄ Ç°10Ìõ

1 Íõºé¶«;³¤ÆÚÐÛ¼¤Ëر©Â¶¶Ô´óÊóÒȵº¦Âϸ°ûGSIS¹¦ÄܵÄÓ°Ïì¼°»úÖÆÑо¿[D];ÄϾ©Ò½¿Æ´óѧ;2015Äê

2 Ã×±¦Ã÷;Á½ÖÖÒȵº¦Âϸ°ûPETÏÔÏñ̽ÕëµÄÖƱ¸ÓëʵÑéÑо¿[D];ËÕÖÝ´óѧ;2016Äê

3 ËïÁ¦;¹Â¶ùºËÊÜÌåNR2E1ÔÚ2ÐÍÌÇÄò²¡·¢²¡»úÖÆÖеÄÑо¿[D];Î人´óѧ;2015Äê

4 ÓÈÎÀ¾ø;miR-24ÔÚÌÇÄò²¡Òȵº¦Âϸ°ûËðÉËÖеÄ×÷ÓúͻúÖÆÑо¿[D];ÄϾ©Ò½¿Æ´óѧ;2016Äê

5 ʯСÀö;ºËÊÜÌåTLXÔÚÒȵº¦Âϸ°ûËðÉËÐÞ¸´ÖеÄ×÷Óü°»úÖÆÑо¿[D];Î人´óѧ;2016Äê

6 ³ÂÖ¾ºì;ЯÓÐÊóÒȵºËØÑùÉú³¤Òò×Ó1ÖØ×éÏÙ²¡¶¾¶ÔÒȵº¦Âϸ°ûµÄ±£»¤ÐÔÑо¿[D];ɽ¶«´óѧ;2009Äê

7 Áè¼Ò¼ó;Ò»Ñõ»¯µªÔÚÒȵº¦Âϸ°ûÄÚ¶Ô»·¼ÓÑõø2±í´ï¡¢Ç°ÁÐÏÙËØE2ºÏ³ÉµÄÓ°Ïì¼°Ç°ÁÐÏÙËØE2ÒýÆðÒȵº¦Âϸ°û¹¦ÄÜÎÉÂÒ×÷ÓûúÖƵÄÑо¿[D];ÄϾ©Ò½¿Æ´óѧ;2005Äê

8 ÀîÃô;¸ßǨÒÆÂÊ×åµ°°×1ÔÚ1ÐÍÌÇÄò²¡ÊóÒȵº¦Âϸ°ûËðÉËÖеÄ×÷ÓûúÖÆ[D];¸´µ©´óѧ;2012Äê

9 Áú½¡;Ö¬ÁªËØÒÖÖÆÒȵº¦Âϸ°ûÖ¬ÐÔµòÍö¼°Æä»úÖÆÑо¿[D];ÖØÇìÒ½¿Æ´óѧ;2012Äê

10 ³ÂÎıó;±í¹ÛÒÅ´«µ÷¿Ø¶ÔÒȵº¦Âϸ°û·¢ÓýºÍ¹¦ÄÜÒÔ¼°ÌÇÄò²¡·¢²¡µÄÓ°ÏìºÍ»úÖÆ[D];ɽ¶«´óѧ;2013Äê

Ïà¹Ø˶ʿѧλÂÛÎÄ Ç°10Ìõ

1 ¸ÊÇïÀ¼;Î÷¸ñÁÐÍ¡Þ׿¹ÌÇÄò²¡Òȵº¦Âϸ°ûÑ×Ö¢·´Ó¦¼°ÓëKeap1-Nrf2-AREͨ·µÄ¹Øϵ[D];¸£½¨Ò½¿Æ´óѧ;2015Äê

2 ÌÆȽç÷;»ùÓڰеãPTP1BµÄÒȵº¦Âϸ°û±£»¤µÄʵÑéÑо¿¼°¿¹´úл×ÛºÏÕ÷Ò©Îïɸѡ[D];±±¾©Ð­ºÍҽѧԺ;2015Äê

3 ÃçÌìÒí;Æ»¹û¶à·Ó»ùÓÚGLP-1ÊÜÌå;¾¶½µÌÇ×÷ÓõĻúÖÆÑо¿[D];ºÓ±±Ò½¿Æ´óѧ;2015Äê

4 ÕŽ¨Î°;ÁÁ°±Ëá¶Ô2ÐÍÌÇÄò²¡µÄÓ°Ïì[D];ËÕÖÝ´óѧ;2015Äê

5 Áõäýäý;µÖµ±ÜιðÌÀ¶ÔÌÇÄò²¡´óÊóFFA¡¢ADPN¼°Òȵº¦Âϸ°û½á¹¹Ó°ÏìµÄʵÑéÑо¿[D];ÉÂÎ÷ÖÐÒ½Ò©´óѧ;2015Äê

6 лÐÄÃç;IrisinÓëbetatrophinµÄ¹ØϵÒÔ¼°¶Ô¦Âϸ°ûÔöÖ³×÷ÓõÄÑо¿[D];ÄÏ·½Ò½¿Æ´óѧ;2015Äê

7 ÐÏÔÆÖ¥;ɳ¸ñÁÐͨ͡¹ýÒÖÖÆSDF-1¦Á½µ½â´Ù½ø2ÐÍÌÇÄò²¡´óÊóÒȵº¦Âϸ°ûÔöÖ³×÷ÓõÄÑо¿[D];Ìì½òÒ½¿Æ´óѧ;2015Äê

8 ¸ßÀöÀö;PKRµ°°×½áºÏ¹¦ÄÜ´Ù½øÒȵº¦Âϸ°ûÔöÖ³»úÖÆÑо¿[D];ÄϾ©Ò½¿Æ´óѧ;2015Äê

9 ÍðÏþÃÎ;PKR¼¤»îͨ¹ýSUMO»¯ÐÞÊÎÉϵ÷P53ÒÖÖÆÒȵº¦Âϸ°ûÔöÖ³[D];ÄϾ©Ò½¿Æ´óѧ;2015Äê

10 ½¹³É;ÂýÐÔ¼äЪÐÔµÍÑõÏÂmTORÐźÅͨ·±ä»¯¶Ô´óÊóÒȵº¦Âϸ°ûÊýÁ¿µÄÓ°Ïì[D];ÄϾ©Ò½¿Æ´óѧ;2015Äê

£¬

±¾ÎıàºÅ£º2361740

×ÊÁÏÏÂÔØ
ÂÛÎÄ·¢±í

±¾ÎÄÁ´½Ó£ºhttps://www.wllwen.com/yixuelunwen/nfm/2361740.html


Copyright(c)ÎÄÂÛÂÛÎÄÍøAll Rights Reserved | ÍøÕ¾µØͼ |

°æȨÉêÃ÷£º×ÊÁÏÓÉÓû§56ef2***Ìṩ£¬±¾Õ¾½öÊÕ¼ժҪ»òĿ¼£¬×÷ÕßÐèҪɾ³ýÇëE-mailÓÊÏäbigeng88@qq.com